{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:13:51Z","timestamp":1788606831668,"version":"build-2803163510"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.nano.2026.103007","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:59:54Z","timestamp":1787669994000},"page":"103007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Engineering CRISPR nanoplatforms to deplete cancer stem cells: Delivery checkpoints, target plasticity, and clinical viability"],"prefix":"10.1016","volume":"76","author":[{"given":"Selvakumar","family":"Chandrasekaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nallusamy","family":"Duraisamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunathan","family":"Jagadeesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashwanth Kumar","family":"Palukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silambarasan","family":"Tamilselvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.nano.2026.103007_bb0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.20517\/cdr.2023.23","article-title":"Cancer stem cells in drug resistance: an introduction to the e-book covering the special issue on the \u201cCancer stem cells and drug resistance\u201d","volume":"6","author":"Sarkadi","year":"2023","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12935-024-03558-0","article-title":"Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy","volume":"24","author":"Mengistu","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"12","key":"10.1016\/j.nano.2026.103007_bb0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.20892\/j.issn.2095-3941.2023.0333","article-title":"Cancer stem cells: a target for overcoming therapeutic resistance and relapse","volume":"20","author":"Zhang","year":"2024","journal-title":"Cancer Biol Med"},{"issue":"4","key":"10.1016\/j.nano.2026.103007_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040976","article-title":"Dissecting tumor growth: the role of cancer stem cells in drug resistance and recurrence","volume":"14","author":"Aramini","year":"2022","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.nano.2026.103007_bb0025","article-title":"Mechanisms on chemotherapy resistance of colorectal cancer stem cells and research progress of reverse transformation: a mini-review","volume":"9","author":"Chen","year":"2022","journal-title":"Front Med (Lausanne)."},{"issue":"9","key":"10.1016\/j.nano.2026.103007_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092613","article-title":"The role of hypoxia and cancer stem cells in development of glioblastoma","volume":"15","author":"Shi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.nano.2026.103007_bb0035","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s13402-025-01102-4","article-title":"Revealing genetic drivers of ovarian cancer and chemoresistance: insights from whole-genome CRISPR-knockout library screens","volume":"48","author":"Skipper","year":"2025","journal-title":"Cell Oncol"},{"key":"10.1016\/j.nano.2026.103007_bb0040","article-title":"Editorial: aldehyde dehydrogenase in clinical settings: potential biomarker and therapeutic target in solid tumors","volume":"9","author":"Aramini","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.nano.2026.103007_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032122","article-title":"Re-sensitizing Cancer stem cells to conventional chemotherapy agents","volume":"24","author":"Kim","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12943-023-01925-5","article-title":"Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy","volume":"23","author":"Chehelgerdi","year":"2024","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s11658-023-00483-4","article-title":"CRISPR applications in cancer diagnosis and treatment","volume":"28","author":"Wang","year":"2023","journal-title":"Cell Mol Biol Lett"},{"issue":"6","key":"10.1016\/j.nano.2026.103007_bb0060","doi-asserted-by":"crossref","DOI":"10.34172\/bi.2024.30087","article-title":"CRISPR-Cas9 in basic and translational aspects of cancer therapy","volume":"14","author":"Samareh Salavatipour","year":"2024","journal-title":"Bioimpacts"},{"issue":"2","key":"10.1016\/j.nano.2026.103007_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10474","article-title":"Optimization of CRISPR\u2013Cas system for clinical cancer therapy","volume":"8","author":"Meng","year":"2023","journal-title":"Bioeng Transl Med"},{"issue":"2","key":"10.1016\/j.nano.2026.103007_bb0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41434-024-00499-1","article-title":"Prime editing: therapeutic advances and mechanistic insights","volume":"32","author":"Murray","year":"2025","journal-title":"Gene Ther"},{"issue":"7","key":"10.1016\/j.nano.2026.103007_bb0075","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s12276-025-01463-8","article-title":"Emerging trends in prime editing for precision genome editing","volume":"57","author":"Lee","year":"2025","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.nano.2026.103007_bb0080","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fphar.2025.1552741","article-title":"CRISPR\/Cas9 technology in tumor research and drug development application progress and future prospects [review]","volume":"16","author":"Han","year":"2025","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.nano.2026.103007_bb0085","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/s41417-025-00959-9","article-title":"Gene editing in cancer therapy: overcoming drug resistance and enhancing precision medicine","volume":"32","author":"Park","year":"2025","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.46439\/cancerbiology.6.071","article-title":"Cancer stem cells as a biomarker\u2013a mini review","volume":"6","author":"Joshi","year":"2025","journal-title":"Journal of Cancer Biology"},{"issue":"14","key":"10.1016\/j.nano.2026.103007_bb0095","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.7150\/ijms.112724","article-title":"Overcoming the delivery challenges in CRISPR\/Cas9 gene editing for effective Cancer treatment: a review of delivery systems [review]","volume":"22","author":"Tang","year":"2025","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.nano.2026.103007_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1138596","article-title":"Immunogenicity of CRISPR therapeutics-critical considerations for clinical translation","volume":"11","author":"Ewaisha","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"issue":"7","key":"10.1016\/j.nano.2026.103007_bb0105","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41417-023-00597-z","article-title":"Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR\/Cas-mediated cancer therapy","volume":"30","author":"Ahmadi","year":"2023","journal-title":"Cancer Gene Ther"},{"issue":"15","key":"10.1016\/j.nano.2026.103007_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/cells14151136","article-title":"Nanotechnology-based delivery of CRISPR\/Cas9 for Cancer treatment: a comprehensive review","volume":"14","author":"Rauf","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0115","article-title":"Nanotechnology-based CRISPR\/Cas9 delivery system for genome editing in cancer treatment","volume":"3","author":"Zhou","year":"2024","journal-title":"MedComm Biomater Appl"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0120","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/MS9.0000000000004414","article-title":"Nanoparticle-enhanced CRISPR delivery: paving the path for in vivo tumor gene editing","volume":"88","author":"Khizar","year":"2026","journal-title":"Ann Med Surg (Lond)"},{"issue":"6","key":"10.1016\/j.nano.2026.103007_bb0125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"New England Journal of Medicine."},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0130","article-title":"Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy","volume":"2023","author":"Kotit","year":"2023","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.nano.2026.103007_bb0135","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365."},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1566523222666220831161225","article-title":"CRISPR\/Cas9-based gene therapies for fighting drug resistance mediated by Cancer stem cells","volume":"23","author":"Dashtaki","year":"2023","journal-title":"Curr Gene Ther"},{"issue":"3","key":"10.1016\/j.nano.2026.103007_bb0145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.medj.2022.12.001","article-title":"Cancer nanomedicine toward clinical translation: obstacles, opportunities, and future prospects","volume":"4","author":"Zhang","year":"2023","journal-title":"Med"},{"issue":"23","key":"10.1016\/j.nano.2026.103007_bb0150","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2217\/nnm-2023-0145","article-title":"CD44 targeted delivery of hyaluronic acid-coated polymeric nanoparticles against colorectal cancer","volume":"18","author":"Phatak","year":"2023","journal-title":"Nanomedicine (Lond)"},{"issue":"2024","key":"10.1016\/j.nano.2026.103007_bb0155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev-pathmechdis-051222-122423","article-title":"Update on epithelial-mesenchymal plasticity in cancer progression","volume":"19","author":"Fontana","year":"2024","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"10.1016\/j.nano.2026.103007_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032400","article-title":"The prognostic value of Cancer stem cell markers (CSCs) expression-ALDH1A1, CD133, CD44-for survival and long-term follow-up of ovarian Cancer patients","volume":"24","author":"Izycka","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13193-022-01626-3","article-title":"Cancer stem cell markers - CD133 and CD44 - in Paediatric solid Tumours: a study of Immunophenotypic expression and correlation with Clinicopathological parameters","volume":"14","author":"Singh","year":"2023","journal-title":"Indian J Surg Oncol"},{"key":"10.1016\/j.nano.2026.103007_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760423","article-title":"Hyaluronidase and pH dual-responsive nanoparticles for targeted breast Cancer stem cells","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.nano.2026.103007_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27062557","article-title":"Glioblastoma stem cells and tumour microenvironment: interactions across hypoxia, vasculature and immune modulation","volume":"27","author":"Biserova","year":"2026","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.nano.2026.103007_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042333","article-title":"Employing CRISPR-Cas9 to generate CD133 synthetic lethal melanoma stem cells","volume":"23","author":"Simbulan-Rosenthal","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nano.2026.103007_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsoil.2019.103430","article-title":"Evaluation of the ecological restoration of a coal mine dump by exploring the characteristics of microbial communities","volume":"147","author":"Chen","year":"2020","journal-title":"Appl Soil Ecol"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcb.23350","article-title":"The Wnt\/\u03b2-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer","volume":"113","author":"King","year":"2012","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.nano.2026.103007_bb0195","doi-asserted-by":"crossref","unstructured":"Saran U, Chandrasekaran B, Tyagi A, et al. A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth [original research]. Front Pharmacol 2023 2023-February-24;Volume 14 - 2023.","DOI":"10.3389\/fphar.2023.1150774"},{"key":"10.1016\/j.nano.2026.103007_bb0200","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fcell.2023.1231416","article-title":"Notch receptor\/ligand diversity: contribution to colorectal cancer stem cell heterogeneity [review]","volume":"11","author":"Brisset","year":"2023","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.nano.2026.103007_bb0205","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.3390\/cimb46060323","article-title":"Unravelling the mysteries of the sonic hedgehog pathway in Cancer stem cells: activity, crosstalk and regulation","volume":"46","author":"Berrino","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.nano.2026.103007_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102186","article-title":"Degradable CRISPR\/Cas9 nanosystem activated by NIR-II light targets genome editing of PD-L1 and metabolic modulation for enhanced antitumor immunity","volume":"55","author":"Zhao","year":"2024","journal-title":"Nano Today"},{"issue":"37","key":"10.1016\/j.nano.2026.103007_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202306863","article-title":"Bioorthogonal reaction-mediated tumor-selective delivery of CRISPR\/Cas9 system for dual-targeted cancer immunotherapy","volume":"62","author":"Yang","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.nano.2026.103007_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1274509","article-title":"Editorial: exploring cancer stem cells signaling pathways","volume":"13","author":"Mekapogu","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.nano.2026.103007_bb0225","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16010062","article-title":"Natural biopolymer-based delivery of CRISPR\/Cas9 for cancer treatment","volume":"16","author":"Lin","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.103007_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2020.124688","article-title":"Efficient CRISPR\/Cas9 gene-chemo synergistic cancer therapy via a stimuli-responsive chitosan-based nanocomplex elicits anti-tumorigenic pathway effect","volume":"393","author":"Zhang","year":"2020","journal-title":"Chem Eng J"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-025-02593-8","article-title":"Epithelial-mesenchymal transition in colorectal cancer metastasis and progression: molecular mechanisms and therapeutic strategies","volume":"11","author":"Nie","year":"2025","journal-title":"Cell Death Discov"},{"issue":"13","key":"10.1016\/j.nano.2026.103007_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/polym14132601","article-title":"Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect","volume":"14","author":"Ejigah","year":"2022","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.nano.2026.103007_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2025.214636","article-title":"Enhanced permeability and retention (EPR) effect: advances in nanomedicine for improved tumor targeting","volume":"181","author":"Khan","year":"2026","journal-title":"Biomater Adv"},{"issue":"7","key":"10.1016\/j.nano.2026.103007_bb0260","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s12276-025-01487-0","article-title":"Perturbomics: CRISPR\u2013Cas screening-based functional genomics approach for drug target discovery","volume":"57","author":"Park","year":"2025","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.nano.2026.103007_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125778","article-title":"Synthesis of low molecular weight polyethylene imine-polyamidoamine hybrid and its modified derivatives as efficient nanocarriers for pDNA and CRISPR\/Cas9 delivery","volume":"680","author":"Amiri","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.103007_bb0270","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.actbio.2024.10.030","article-title":"A biodegradable lipid nanoparticle delivers a Cas9 ribonucleoprotein for efficient and safe in situ genome editing in melanoma","volume":"190","author":"Yang","year":"2024","journal-title":"Acta Biomater"},{"issue":"11","key":"10.1016\/j.nano.2026.103007_bb0275","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.nano.2026.103007_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29245997","article-title":"Endosomal escape and nuclear localization: critical barriers for therapeutic nucleic acids","volume":"29","author":"Allen","year":"2024","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.nano.2026.103007_bb0285","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s11095-022-03229-7","article-title":"PAMAM versus PEI complexation for siRNA delivery: interaction with model lipid membranes and cellular uptake","volume":"39","author":"Chang","year":"2022","journal-title":"Pharm Res"},{"issue":"47","key":"10.1016\/j.nano.2026.103007_bb0290","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9450","article-title":"CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci Adv"},{"issue":"6","key":"10.1016\/j.nano.2026.103007_bb0295","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/med.21971","article-title":"(Nano)platforms in breast cancer therapy: drug\/gene delivery, advanced nanocarriers and immunotherapy","volume":"43","author":"Ashrafizadeh","year":"2023","journal-title":"Med Res Rev"},{"issue":"3","key":"10.1016\/j.nano.2026.103007_bb0300","article-title":"Functionalized chitosan as nano-delivery platform for CRISPR-Cas9 in cancer treatment","volume":"20","author":"Nawaz","year":"2025","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.nano.2026.103007_bb0305","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fonc.2022.1054029","article-title":"Tumor microenvironment penetrating chitosan nanoparticles for elimination of cancer relapse and minimal residual disease [review]","volume":"12","author":"Mahmudi","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.nano.2026.103007_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123299","article-title":"Improved biocompatibility of dendrimer-based gene delivery by histidine-modified nuclear localization signals","volume":"644","author":"Lee","year":"2023","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.nano.2026.103007_bb0315","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1073\/pnas.1912220117","article-title":"Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing","volume":"117","author":"Chen","year":"2020","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"10.1016\/j.nano.2026.103007_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/biom12091239","article-title":"Research Progress on nanoparticles-based CRISPR\/Cas9 system for targeted therapy of tumors","volume":"12","author":"Nie","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-33092-4","article-title":"Lipid-coated mesoporous silica nanoparticles for anti-viral applications via delivery of CRISPR-Cas9 ribonucleoproteins","volume":"13","author":"LaBauve","year":"2023","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.nano.2026.103007_bb0330","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1039\/D2TB01858F","article-title":"Graphene family in cancer therapy: recent progress in cancer gene\/drug delivery applications","volume":"11","author":"Borzooee Moghadam","year":"2023","journal-title":"J Mater Chem B"},{"issue":"19","key":"10.1016\/j.nano.2026.103007_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/nano12193323","article-title":"Biocompatible Iron oxide nanoparticles for targeted Cancer gene therapy: a review","volume":"12","author":"Zhang","year":"2022","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.nano.2026.103007_bb0340","article-title":"Iron oxide nanoparticles: the precise strategy for targeted delivery of genes, oligonucleotides and peptides in cancer therapy","volume":"74","author":"Sachdeva","year":"2022","journal-title":"J Drug Deliv Sci Technol"},{"issue":"9","key":"10.1016\/j.nano.2026.103007_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289731","article-title":"Effective gene delivery using size dependant nano core-shell in human cervical cancer cell lines by magnetofection","volume":"18","author":"Sundara Rajan","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.nano.2026.103007_bb0350","doi-asserted-by":"crossref","first-page":"253","DOI":"10.34172\/apb.2024.021","article-title":"Translational challenges in cancer nanotherapy","volume":"14","author":"Ravi Kiran","year":"2024","journal-title":"Adv Pharm Bull"},{"issue":"11","key":"10.1016\/j.nano.2026.103007_bb0355","doi-asserted-by":"crossref","first-page":"10891","DOI":"10.1021\/acsomega.4c08739","article-title":"P53 Gene Therapy with ZIF-8 Metal\u2013Organic Framework: A Platform in Cancer Gene Therapy","volume":"10","author":"Salari","year":"2025","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0360","doi-asserted-by":"crossref","DOI":"10.1002\/smmd.134","article-title":"Biomineralize mitochondria in metal-organic frameworks to promote mitochondria transplantation from non-tumorigenic cells into cancer cells","volume":"4","author":"Zhou","year":"2025","journal-title":"Smart Medicine"},{"issue":"6","key":"10.1016\/j.nano.2026.103007_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1285","article-title":"Cell membrane-coated nanoparticles for the treatment of cancer","volume":"13","author":"Krishnan","year":"2023","journal-title":"Clin Transl Med"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0370","first-page":"33","article-title":"Membrane-coated nanoparticles as a biomimetic targeted delivery system for tumour therapy","volume":"5","author":"Guo","year":"2024","journal-title":"Biomater Transl"},{"issue":"4","key":"10.1016\/j.nano.2026.103007_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16040531","article-title":"Cell membrane-coated biomimetic nanoparticles in Cancer treatment","volume":"16","author":"Zhang","year":"2024","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.nano.2026.103007_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15122770","article-title":"Cell membrane biomimetic Nano-delivery Systems for Cancer Therapy","volume":"15","author":"Xia","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.103007_bb0385","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fonc.2023.1270407","article-title":"Research progress of cancer cell membrane coated nanoparticles for the diagnosis and therapy of breast cancer","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.nano.2026.103007_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155785","article-title":"Exosome-mediated delivery of CRISPR-Cas9: a revolutionary approach to cancer gene editing","volume":"266","author":"Balaraman","year":"2025","journal-title":"Pathol Res Pract"},{"issue":"17","key":"10.1016\/j.nano.2026.103007_bb0395","doi-asserted-by":"crossref","first-page":"16432","DOI":"10.1021\/acsnano.2c12857","article-title":"Engineered extracellular vesicle-delivered CRISPR\/Cas9 for radiotherapy sensitization of glioblastoma","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.nano.2026.103007_bb0400","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000875","article-title":"Exosome-mediated delivery of CRISPR\/Cas9 for targeting of oncogenic Kras(G12D) in pancreatic cancer","volume":"4","author":"McAndrews","year":"2021","journal-title":"Life Sci Alliance"},{"issue":"24","key":"10.1016\/j.nano.2026.103007_bb0405","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415758","article-title":"New therapeutics for extracellular vesicles: delivering CRISPR for cancer treatment","volume":"23","author":"Yan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nano.2026.103007_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1444437","article-title":"Advances in delivery systems for CRISPR\/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.nano.2026.103007_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102040","article-title":"CRISPR-Cas9 delivery strategies with engineered extracellular vesicles","volume":"34","author":"Lu","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"10.1016\/j.nano.2026.103007_bb0420","doi-asserted-by":"crossref","DOI":"10.1002\/jex2.111","article-title":"CRISPR delivery with extracellular vesicles: promises and challenges","volume":"2","author":"Berggreen","year":"2023","journal-title":"Journal of Extracellular Biology"},{"key":"10.1016\/j.nano.2026.103007_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103961","article-title":"A critical review on the dissemination of pH and stimuli-responsive polymeric nanoparticular systems to improve drug delivery in cancer therapy","volume":"185","author":"Bhattacharya","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.nano.2026.103007_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/polym14050936","article-title":"pH-responsive nanocarriers in cancer therapy","volume":"14","author":"AlSawaftah","year":"2022","journal-title":"Polymers (Basel)."},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0435","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-49446-x","article-title":"pH\/redox responsive size-switchable intelligent nanovehicle for tumor microenvironment targeted DOX release","volume":"13","author":"Badparvar","year":"2023","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.nano.2026.103007_bb0440","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1039\/D2BM00315E","article-title":"Nanoparticle personalized biomolecular corona: implications of pre-existing conditions for immunomodulation and cancer","volume":"10","author":"Shaw","year":"2022","journal-title":"Biomater Sci"},{"issue":"16","key":"10.1016\/j.nano.2026.103007_bb0445","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1039\/D2NA00290F","article-title":"Tuning the immune system by nanoparticle-biomolecular corona","volume":"4","author":"Palmieri","year":"2022","journal-title":"Nanoscale Adv"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0450","doi-asserted-by":"crossref","DOI":"10.1186\/s44301-025-00014-4","article-title":"Beyond PEGylation: nanoparticle surface modulation for enhanced cancer therapy","volume":"1","author":"Taghavimandi","year":"2025","journal-title":"Health Nanotechnol"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0455","first-page":"1","article-title":"Mechanistic and translational nanomaterial-based strategies for targeting cancer stem cell resistance","volume":"9","author":"Karunakar","year":"2026","journal-title":"Discov Oncol"},{"key":"10.1016\/j.nano.2026.103007_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103045","article-title":"Progress and challenges in the translation of cancer nanomedicines","volume":"85","author":"Tong","year":"2024","journal-title":"Curr Opin Biotechnol"},{"issue":"5","key":"10.1016\/j.nano.2026.103007_bb0465","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat Rev Mater"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0470","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40824-023-00365-y","article-title":"Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery","volume":"27","author":"Narwade","year":"2023","journal-title":"Biomaterials Research"},{"key":"10.1016\/j.nano.2026.103007_bb0475","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fbioe.2023.1092901","article-title":"Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors [review]","volume":"11","author":"Yin","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"issue":"24","key":"10.1016\/j.nano.2026.103007_bb0480","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202201293","article-title":"Red blood cell anchoring enables targeted transduction and re-administration of AAV-mediated gene therapy","volume":"9","author":"Zhao","year":"2022","journal-title":"Adv Sci"},{"issue":"15","key":"10.1016\/j.nano.2026.103007_bb0485","article-title":"Nanoengineered red blood cells loaded with TMPRSS2 and Cathepsin L inhibitors block SARS-CoV-2 pseudovirus entry into lung ACE2+ cells","volume":"36","author":"Yang","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.nano.2026.103007_bb0490","article-title":"Advanced strategies for overcoming endosomal\/lysosomal barrier in nanodrug delivery","volume":"6","author":"Qiu","year":"2023","journal-title":"Research (Wash D C)"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0495","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-22-0243","article-title":"Targeting the DLL\/notch signaling pathway in Cancer: challenges and advances in clinical development","volume":"22","author":"You","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0500","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s11033-021-06832-w","article-title":"Insights of CRISPR-Cas systems in stem cells: progress in regenerative medicine","volume":"49","author":"Dilip Kumar","year":"2022","journal-title":"Mol Biol Rep"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0505","article-title":"The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer","volume":"5","author":"He","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.nano.2026.103007_bb0510","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.nano.2026.103007_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102666","article-title":"Advancing gene editing therapeutics: clinical trials and innovative delivery systems across diverse diseases","volume":"36","author":"Raigani","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"10.1016\/j.nano.2026.103007_bb0520","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.apsb.2024.04.033","article-title":"Triterpenoids-templated self-assembly nanosystem for biomimetic delivery of CRISPR\/Cas9 based on the synergy of TLR-2 and ICB to enhance HCC immunotherapy","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0525","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12951-024-02571-9","article-title":"Tumor microenvironment responsive nano-herb and CRISPR delivery system for synergistic chemotherapy and immunotherapy","volume":"22","author":"Jia","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.nano.2026.103007_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121871","article-title":"Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy","volume":"291","author":"Lu","year":"2022","journal-title":"Biomaterials"},{"issue":"18","key":"10.1016\/j.nano.2026.103007_bb0535","doi-asserted-by":"crossref","first-page":"9880","DOI":"10.1093\/nar\/gkad702","article-title":"Guide-specific loss of efficiency and off-target reduction with Cas9 variants","volume":"51","author":"Zhang","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nano.2026.103007_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117516","article-title":"Optimizing CRISPR\/Cas9 precision: mitigating off-target effects for safe integration with photodynamic and stem cell therapies in cancer treatment","volume":"180","author":"Merlin","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0545","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0550","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12943-022-01565-1","article-title":"CRISPR\/Cas9 and next generation sequencing in the personalized treatment of cancer","volume":"21","author":"Selvakumar","year":"2022","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.nano.2026.103007_bb0555","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/crispr.2021.0120","article-title":"ON-target adverse events of CRISPR-Cas9 nuclease: more chaotic than expected","volume":"5","author":"Boutin","year":"2022","journal-title":"Crispr j"},{"key":"10.1016\/j.nano.2026.103007_bb0560","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing [mini review]","volume":"11","author":"Guo","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.nano.2026.103007_bb0565","first-page":"21","article-title":"Recent advancements in reducing the off-target effect of CRISPR-Cas9 genome editing","volume":"18","author":"Asmamaw Mengstie","year":"2024","journal-title":"Biologics"},{"key":"10.1016\/j.nano.2026.103007_bb0570","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/erm.2025.10","article-title":"Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects","volume":"27","author":"Cetin","year":"2025","journal-title":"Expert Rev Mol Med"},{"issue":"18","key":"10.1016\/j.nano.2026.103007_bb0575","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1016\/j.nano.2026.103007_bb0580","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"New England Journal of Medicine."}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426001085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426001085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:10:35Z","timestamp":1788606635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963426001085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":116,"alternative-id":["S1549963426001085"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2026.103007","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering CRISPR nanoplatforms to deplete cancer stem cells: Delivery checkpoints, target plasticity, and clinical viability","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2026.103007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103007"}}